The protopine alkaloids are widely distributed within the opium poppy family and have a wide range of pharmacological effects. MPTA is a product of the protopine total alkaloids extracted from the (Willd.) R. Br. Previously, we reported good anti-inflammatory activity of MPTA as well as oral acute and sub-chronic toxicity studies in rats. In order to perform a systematic toxicological safety assessment of MPTA, oral acute toxicity, genotoxicity (bone marrow cell chromosome aberration test, sperm abnormality test, bone marrow cell micronucleus test, and rat teratogenicity test), and chronic toxicity in mice were performed in this study. In the oral acute toxicity test, the LD in ICR mice was 481.99 mg/kg, with 95% confidence limits ranging from 404.27 to 574.70 mg/kg. All three mutagenicity tests tested negative in the range of 60.25-241.00 mg/kg. The results of the teratogenicity test in rats showed no reproductive or embryonic developmental toxicity at only 7.53 mg/kg, which can be considered as a no observed effect level (NOEL) for the teratogenicity test. Therefore, MPTA is safe for use at the doses tested, but attention should be paid to the potential risk to pregnant animals and the safety evaluation and toxicity mechanisms in target animals should be further investigated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554591PMC
http://dx.doi.org/10.3389/fphar.2022.987800DOI Listing

Publication Analysis

Top Keywords

oral acute
12
teratogenicity test
12
protopine total
8
total alkaloids
8
acute toxicity
8
bone marrow
8
marrow cell
8
test
7
toxicity
6
acute
4

Similar Publications

Polymicrobial empyema in a patient with lung adenocarcinomacontaining .

BMJ Case Rep

January 2025

Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania, USA.

A man in his 60s with advanced COPD and lung adenocarcinoma presented with sepsis and acute hypoxaemic respiratory failure. Imaging revealed bilateral pleural effusions, and he was found to have a polymicrobial empyema which included Despite appropriate treatment, he continued to deteriorate and ultimately died of sepsis. species, typically benign constituents of the oral microbiota, rarely can instigate pleuropulmonary infections, especially in immunocompromised individuals.

View Article and Find Full Text PDF

Introduction: This study examined the association between cardiovascular disease (CVD) history and their dental caries experience status.

Methods: Conducted from January 2021 to June 2023, this cross-sectional cohort study involved 7,138 participants who underwent oral examinations. Data on demographic background, oral health-related behaviors, and smoking status were collected using a structured questionnaire.

View Article and Find Full Text PDF

Local health departments can play a critical role in zoonoses surveillance at the human-domestic animal interface, especially when existing public health services and close relationships with community groups can be leveraged. Investigators at Harris County Veterinary Public Health employed a community-based surveillance tool for identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in dogs and cats in June--December 2021. Diagnosis was made using both RT-qPCR testing of oral and nasal swabs and plaque reduction neutralization testing of serum samples.

View Article and Find Full Text PDF

Nonantibiotic strategies are urgently needed to treat acute drug-resistant bacterial pneumonia. Recently, nanomaterial-mediated bacterial cuproptosis has arisen widespread interest due to its superiority against antibiotic resistance. However, it may also cause indiscriminate and irreversible damage to healthy cells.

View Article and Find Full Text PDF

Andexanet alfa: trials just leave us with more questions.

Res Pract Thromb Haemost

January 2025

Department of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to andexanet alfa or usual care, was mandated by the United States Food and Drug Administration as part of its conditional approval in 2018. This approval was originally based on the single-arm trial, The Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!